Every pharmaceutical patent filed with the FDA Orange Book names two things: who owns the invention, and who made it. […]

Most biotech executives say they allocate R&D capital rationally. Most are wrong. They favor programs with internal champions, compounds that

Between 2025 and 2030, the pharmaceutical industry will lose exclusivity on drugs generating more than $300 billion in annual revenue.

You probably already know the number: 80 to 90 percent. That’s how much of a branded small-molecule drug’s revenue can

Before a pharmaceutical company files a single WARN notice, before a restructuring plan hits an SEC filing, before a CEO

Colchicine cost nine cents a pill for more than two centuries. Then, in 2009, a company ran a 185-patient trial

Every biosimilar switch strategy that fails, fails at the same point: someone made a sourcing decision based on the manufacturer’s

How life sciences talent teams can map influence networks, identify hidden innovators, and outmaneuver competitors using publicly available IP data

Colchicine cost nine cents a pill for more than two centuries. Then, in 2009, a company ran a 185-patient trial